Mindfulness, Yoga, and Cardiovascular Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00696852
Recruitment Status : Completed
First Posted : June 13, 2008
Last Update Posted : September 24, 2012
Information provided by (Responsible Party):
Joan Fox, The Cleveland Clinic

Brief Summary:

In this study, we will conduct a preliminary, yet comprehensive evaluation of Mindfulness and Yoga, as compared to an exercise and education-based stress-reduction program. and simultaneous evaluation of the effect of an 8 week program of Mindfulness, 12 weeks of Yoga practice, and 12 weeks of an exercise and education-based program.

105 otherwise healthy individuals, who have cardiovascular risk factors and mild to moderate stress or anxiety will be randomly assigned to one of the three intervention groups: an 8 week program of Mindfulness, 12 week program of Yoga practice, and 12 week exercise and education-based group program. All subjects will perform daily practice that will continue after the weekly sessions end, allowing a follow up assessment at 24 weeks. Self-reported mood and psychological distress and physiological indicators of function of the ANS and stress hormones will be assessed at baseline, 8 weeks, 12 weeks and 24 weeks. Blood and urine samples will be collected at baseline and 8 weeks to determine levels inflammatory and atherosclerosis markers.

We anticipate that the study will provide information on the efficacy of the Mindfulness and Yoga interventions as stress-reduction practices, variability in potential markers for activation of the brain/cardiovascular system connections, and preliminary estimates of effect size for each of these markers. Thus, the study will provide the data needed for designing a future study that will rigorously address these questions in a larger, randomized trial of Mindfulness and Yoga in patients with cardiovascular risk.

Condition or disease Intervention/treatment Phase
Cardiovascular Disease Stress Anxiety Depression Behavioral: Mindfulness Meditation Behavioral: Yoga Behavioral: Exercise, Relaxation, and Health Education Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Mindfulness and Yoga on Heart Rate Variability and Immune Markers
Study Start Date : June 2008
Actual Primary Completion Date : May 2009
Actual Study Completion Date : May 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety

Arm Intervention/treatment
Active Comparator: Mindfulness Meditation Behavioral: Mindfulness Meditation
The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
Other Name: MBSR

Active Comparator: Yoga Behavioral: Yoga
The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.

Active Comparator: Conventional Stress Reduction Behavioral: Exercise, Relaxation, and Health Education
The Exercise, Relaxation and Health Education program will consist of a 90 min group session that will include simple relaxation (such as progressive muscle relaxation) and light stretching exercises, group support, and discussions of various health topics and on stress reduction.
Other Name: Progressive muscle relaxation

Primary Outcome Measures :
  1. change in inflammatory markers [ Time Frame: within 26 weeks of enrollment ]

Secondary Outcome Measures :
  1. change in psychological and physiological markers of anxiety, depression, and cardiovascular disease [ Time Frame: within 26 weeks from enrollment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • between the age of 40 and 75
  • A Framingham score >10
  • A DASS-21 anxiety score >5
  • A DASS-21 stress score >10
  • A DASS-21 depression score > than 6
  • A systolic blood pressure > 140
  • A diastolic blood pressure > 90
  • Diagnosed with diabetes
  • Willing to accept randomization into and participation in one of the three intervention programs: Mindfulness, Yoga, or Conventional Stress Reduction

Exclusion Criteria:

  • Already practicing Mindfulness, Yoga, or similar meditative mind-body practices on a weekly basis
  • Already enrolled in a lifestyle modification program including exercise or diet program
  • Yoga or meditation be incompatible with religious or philosophical beliefs
  • Experienced a major stressful life event in the last three months prior to the beginning of the intervention that is likely to affect the outcomes of the study
  • Currently being treated or on medications for psychiatric conditions, including depression, anxiety, anger, or hostility
  • A depression score >20 on the DASS-21 questionnaire
  • A history of myocardial disease, peripheral vascular disease, cerebrovascular disease, atrial fibrillation, pacemaker placement, heart failure, valvular heart disease, congenital heart disease, Wolf-Parkinson White Syndrome, cardiomyopathy, or severe left ventricular systolic dysfunction
  • Take melatonin supplements or any herbal supplement that contains melatonin or 5-LO inhibitors (turmeric, curcumin, ginger and frankincense herbal extracts)
  • Currently using any drugs that contain beta-adrenergic blocking agents, beta-agonists, glucocorticoids, psychotropic medications, drugs that block 5-LO pathway (zileuton, monetlukast), TNF-a blocking agents (infliximab, etanercept, adalimumab)
  • A planned change in blood pressure, anticoagulant medication and lipids lower agents (such as aspirin, statin and plavix) 1 month prior and during the intervention
  • Asthma, obstructive pulmonary disease, or any other respiratory disease
  • Pregnant or breastfeeding
  • An active/chronic infection, cancer, connective tissue, or other inflammatory disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00696852

United States, Ohio
The Cleveland Clinic
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
The Cleveland Clinic
Principal Investigator: Joan EB Fox, Ph.D. The Cleveland Clinic

Responsible Party: Joan Fox, Staff, The Cleveland Clinic Identifier: NCT00696852     History of Changes
Other Study ID Numbers: BHBI-1201
First Posted: June 13, 2008    Key Record Dates
Last Update Posted: September 24, 2012
Last Verified: September 2012

Keywords provided by Joan Fox, The Cleveland Clinic:
Inflammatory Markers

Additional relevant MeSH terms:
Cardiovascular Diseases